Marshall Wace
AUPH icon

Marshall Wace’s Aurinia Pharmaceuticals AUPH Stock Holding History

Marshall Wace’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.7M Buy
2,044,007
+169,410
+9% +$2.71M 0.03% 504
2026
Q1 		$27.8M Buy
1,874,597
+299,640
+19% +$4.38M 0.03% 581
2025
Q4 		$25.1M Buy
1,574,957
+91,825
+6% +$1.3M 0.02% 555
2025
Q3 		$16.4M Buy
1,483,132
+1,375,072
+1,273% +$15M 0.02% 740
2025
Q2 		$915K Buy
+108,060
New +$866K ﹤0.01% 1893
2023
Q4 		– Sell
-24,506
Closed -$190K – 2166
2023
Q3 		$190K Buy
+24,506
New +$240K ﹤0.01% 1981
2023
Q1 		– Sell
-194,281
Closed -$839K – 2643
2022
Q4 		$839K Buy
+194,281
New +$1.13M ﹤0.01% 2162
2022
Q2 		– Sell
-107,318
Closed -$1.33M – 3403
2022
Q1 		$1.33M Sell
107,318
-95,674
-47% -$1.48M ﹤0.01% 2314
2021
Q4 		$4.64M Buy
+202,992
New +$4.81M 0.01% 1411
2020
Q3 		– Sell
-18,740
Closed -$303K – 1561
2020
Q2 		$303K Buy
+18,740
New +$300K ﹤0.01% 1325

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace's AUPH Position: Q2 2026 in Review

Marshall Wace increased its Aurinia Pharmaceuticals (AUPH) stake by 9% in Q2 2026, buying an estimated $2.71M and bringing the position to 2,044,007 shares worth $34.7M. The position accounts for 0.03% of the portfolio, ranked #504.

Marshall Wace first reported a position in AUPH in Q2 2020 and has held it in 10 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Marshall Wace held 2,044,007 shares of Aurinia Pharmaceuticals worth $34.7M as of Q2 2026.
  • Marshall Wace bought 169,410 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $2.71M.
  • Aurinia Pharmaceuticals made up 0.03% of Marshall Wace's portfolio in Q2 2026, its #504 holding.
  • Marshall Wace first reported a position in Aurinia Pharmaceuticals in Q2 2020 and has held it in 10 quarters since.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.